Dulac Edward J III 4
4 · Intellia Therapeutics, Inc. · Filed Jul 25, 2025
Insider Transaction Report
Form 4
Dulac Edward J III
EVP, Chief Financial Officer
Transactions
- Sale
Common Stock
2025-07-23$14.02/sh−7,462$104,617→ 106,062 total
Footnotes (1)
- [F1]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2025, and does not represent a volitional trade by the Reporting Person.